Spotlight -

Drug Development|

Quality Systems

|Articles|April 28, 2023

Discussing Sterile Aseptic Connectors with Todd Andrews (INTERPHEX 2023)

Author(s)Grant Playter

Todd Andrews, global director of Applications and Business Development at CPC, discusses sterile aseptic connectors, flexibility in manufacturing, and more in an interview held at INTERPHEX 2023.

Todd Andrews, global director of Applications and Business Development at CPC, discusses sterile aseptic connectors, flexibility in manufacturing, and more in an interview held at INTERPHEX 2023.

For more INTERPHEX 2023 video content, check this page for updates.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2

October 8th, 2026

CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2

Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.

CPHI Milan 2026: The Demand for Commercial Spray Drying

October 8th, 2026

CPHI Milan 2026: The Demand for Commercial Spray Drying

Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.

Ron Scarboro, Azurity Pharmaceuticals

October 7th, 2026

CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care

Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.

Trophy and confetti on light background, top view with space for text. Victory concept | Image Credit: ©New Africa -stock.adobe.com

October 6th, 2026

Winners of the 2026 CPHI Pharma Awards Announced

The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.

Ron Scarboro, Azurity Pharmaceuticals

October 5th, 2026

CPHI Milan: Why End-to-End Pathway Ownership Matters

Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.

PharmTech Weekly Roundup—October 16, 2026: Rare Diseases, CMC, and AI Accountability

October 16th, 2026

PharmTech Weekly Roundup—October 16, 2026: Rare Diseases, CMC, and AI Accountability

AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.

AstraZeneca taps insitro’s AI to find new MASH and cardiomyopathy targets in a $40M upfront deal.

October 15th, 2026

MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI

MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.

Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1

October 15th, 2026

Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1

Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.

Trending on Pharmaceutical Technology

Germany’s Medical Biotechnology Sector is Flourishing

MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI

Formulation Strategies for Next-Generation Multiagonists

First-in-Human Trial Speed: Why FDA Trails China

PharmTech AI Pulse Check: Why Pharma Should Weigh In on FDA's Generative AI Paper